Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Pembrolizumab in Combination with Gemcitabine in Patients with Advanced Mycosis Fungoides and Sezary Syndrome

Trial Status: closed to accrual

This phase II trial tests whether pembrolizumab in combination with gemcitabine work to shrink tumors in patients with mycosis fungoides and Sezary syndrome that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab in combination with gemcitabine may shrink or stabilize lymphomas such as mycosis fungoides and Sezary syndrome.